Tag: $Merck KgaA

Germany’s Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Merck KGaA (MRCG.DE),  has struck a deal to buy U.S. biotech company SpringWorks Therapeutics (SWTX.O),  for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

Merck’s stock slides as Q3 earnings beat estimates, but company lowers guidance

Merck & Co. Inc.’s stock fell 3% Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to charges stemming from deals with partners Curon Biopharmaceutical and Daiichi Sankyo.